Technology
Estrella is extending the curative power of T-cell therapies to more cancer indications by combining CD19-Redirected ARTEMIS T Cells with cancer-labeling technology.
Estrella Immunopharma, a clinical-stage biopharmaceutical firm, develops CD19 and CD22-targeted ARTEMIS T-cell therapies.
estrellabio.comCrawled Nov 17, 2026
Estrella is extending the curative power of T-cell therapies to more cancer indications by combining CD19-Redirected ARTEMIS T Cells with cancer-labeling technology.
Lymphoma is a cancer of the lymphatic system, which is part of the body’s immune system.
Estrella focuses on creating novel T-cell therapies for areas with unmet medical needs.
A phase I/II clinical trial of EB103 T cells in adult subjects with advanced r/r B-cell NHL.
Patients with relapsed/refractory (R/R) aggressive B-cell Non-Hodgkin’s Lymphomas (NHLs) face challenging prognosis:
An accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning advanced therapies, clinical development, commercialization, strategic partnerships and capital formation
Estrella Immunopharma announced its CEO and CFO will attend one-on-one investor meetings at the D. Boral Capital 2026 Global Conference.
Patient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed through the first month of follow-up
Estrella Immunopharma Highlights ARTEMIS T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Estrella develops T-cell therapies targeting cancer and autoimmune diseases to address unmet treatment needs.
Code of Business Ethics and Conduct Policy
Estrella Immunopharma, Inc. | Extending the frontier of T-cell immunotherapy to cure more cancers.
Estrella Immunopharma presents preclinical data for its ARTEMIS® T-cell therapy at ASH 2026, showing deep and sustained leukemia responses. The therapy outperforms conventional CAR-T in clearing extramedullary disease in model studies. Researchers emphasize its potential for improved patient outcomes in refractory blood cancers.
Estrella Immunopharma administers two doses of its experimental therapy **EB103** to the first patient in the **STARLIGHT-1** dose-expansion phase. The trial evaluates escalating doses of EB103, a potential treatment for autoimmune diseases. This marks a progression in testing the drug’s safety and efficacy beyond initial dose-finding stages.
Estrella Immunopharma expands its **STARLIGHT-1 Phase I/II trial** by activating **University Hospitals Cleveland Medical Center** as its fourth clinical site. The trial evaluates **EB103**, a **CD19-Redirected ARTEMIS T-cell therapy**, for patients with **relapsed or refractory B-cell non-Hodgkin’s lymphoma**. The company continues testing this experimental immunotherapy in ongoing research.
Estrella Immunopharma secures **$8.0 million** through a **registered direct offering** and a **concurrent private placement**. The funding supports the company’s growth and operational expansion in immunopharmaceutical development. No additional details on allocation or use of funds are provided in the announcement.